Physicochemical and biological characterisation of an antisense oligonucleotide targeted against the bcl-2 mRNA complexed with cationic-hydrophilic copolymers

Author： Read M.L.   Dash P.R.   Clark A.   Howard K.A.   Oupicky D.   Toncheva V.   Alpar H.O.   Schacht E.H.   Ulbrich K.   Seymour L.W.  

Publisher： Elsevier

ISSN： 0928-0987

Source： European Journal of Pharmaceutical Sciences, Vol.10, Iss.3, 2000-05, pp. : 169-177

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Enhanced bioavailability of orally administered antisense oligonucleotide to nuclear factor kappa B mRNA after microencapsulation with albumin

By Uddin Mohammad Nasir  

Journal of Drug Targeting, Vol. 21, Iss. 5, 2013-05 ,pp. : 450-457

Informa Healthcare

Access to resources Recommend Favorite

Bcl-2 Antisense in the Treatment of Human Malignancies: A Delusion in Targeted Therapy

By  

Current Pharmaceutical Biotechnology, Vol. 8, Iss. 6, 2007-12 ,pp. : 373-381

Bentham Science Publishers

Access to resources Recommend Favorite

Oblimersen: Augmerosen, BCL-2 Antisense Oligonucleotide - Genta, G 3139, GC 3139, Oblimersen Sodium

By Adis International Limited  

Drugs in R&D, Vol. 8, Iss. 5, 2007-01 ,pp. : 321-334

Adis International

Access to resources Recommend Favorite

G 3139: Augmerosen, Bcl-2 Antisense Oligonucleotide - Genta, GC 3139, Genasense

By  

Drugs in R&D, Vol. 3, Iss. 1, 2002-01 ,pp. : 44-49

Adis International

Access to resources Recommend Favorite

Attenuation of Bleomycin-Induced Pulmonary Fibrosis by Intratracheal Administration of Antisense Oligonucleotides Against Angiotensinogen mRNA

By  

Current Pharmaceutical Design, Vol. 13, Iss. 12, 2007-04 ,pp. : 1257-1268

Bentham Science Publishers

Access to resources Recommend Favorite